"I should like to save the Shire, if I could," J.R.R. Tolkien, The Fellowship of the Ring.
British rare disease specialist Shire PLC (NASDAQ: SHPG )
has become a hot property in this latest round of pharmaceutical
merger mania. Not only does Shire offer a relatively low tax rate by
virtue of its Irish corporate domicile, the company's focus on rare
diseases fits in with the desire of many pharmaceutical companies to
focus on therapeutic areas where reimbursement is high and the barriers
to entry are substantial.
That Shire continues to get marriage offers is no guarantee that it will consent to do so. Not unlike AstraZeneca, Shire sees itself as a buyer, not a seller, and it may well take a prohibitively high number to seal a deal.
Follow this link to the full article:
Will Shire's Journey End in a Ring?
No comments:
Post a Comment